Jointown Pharmaceutical Group (SHA:600998), through its unit Beijing Jingfeng Pharmaceutical Group, obtained a drug registration certificate from China's National Medical Products Administration for betamethasone sodium phosphate injection, according to a Shanghai bourse disclosure on Thursday.
The drug is used to treat allergic and autoimmune inflammatory diseases, such as rheumatoid arthritis, severe bronchial asthma, and severe dermatitis.
The certificate is valid until May 26, 2030, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.